COMMUNIQUÉS West-GlobeNewswire
-
Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting
21/04/2026 -
Eclipse Energy and Wood to Scale Hydrogen Production from End-of-Life Oil Fields
21/04/2026 -
Le Gala de la Fondation de l’Hôpital de Lachine recueille 322 115 $ pour transformer les soins de santé dans l’Ouest-de-l’Île
21/04/2026 -
Lachine Hospital Foundation Gala raises $322,115 to transform health care in the West Island
21/04/2026 -
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Enters Phase Ⅱ Trial with First Patient Dosing in Gastric Cancer, Pioneering Enhanced Immunotherapy Combination Strategies
21/04/2026 -
ImPact Biotech Announces Upcoming Data Presentations for Padeliporfin VTP at AUA and ASCO 2026
21/04/2026 -
Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026
21/04/2026 -
ACTG Launches Critical Study Evaluating Hormone Therapy for Women Living with HIV in the Menopause Transition
21/04/2026 -
Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting
21/04/2026 -
Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026
21/04/2026 -
Dewpoint Therapeutics Reports Preclinical Data on Oral MYC Condensate Modulator at AACR 2026
21/04/2026 -
GLP Diet App Launches Personalized Wellness App for GLP-1 Medication Users, Earns 2,500+ App Reviews
21/04/2026 -
Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting
21/04/2026 -
Trethera Announces Appointment of M. Andrew (“Drew”) Woodmansee to Board of Directors
21/04/2026 -
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
21/04/2026 -
ITM to Announce Quality of Life Data from the Phase 3 COMPETE Trial in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at ASCO 2026
21/04/2026 -
Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer
21/04/2026 -
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
21/04/2026 -
Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
21/04/2026
Pages